Financial Performance - The company's revenue for Q1 2025 was ¥69,775,938.28, a decrease of 65.10% compared to ¥199,953,044.93 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥9,854,658.34, representing a decline of 140.50% from a profit of ¥24,334,978.24 in the previous year[5] - The basic earnings per share for the period was -¥0.07, down 141.18% from ¥0.17 in the same period last year[5] - Net profit for the period was a loss of ¥9,706,327.17 compared to a profit of ¥24,389,323.96 in the previous period, indicating a significant downturn[18] - The company's net profit margin and future guidance were not explicitly detailed in the provided documents[12] Cash Flow and Operating Activities - The net cash flow from operating activities improved to -¥6,488,555.71, a 60.53% increase compared to -¥16,439,476.59 in the same period last year[5] - Operating cash flow net amount was a negative ¥6,488,555.71, an improvement from a negative ¥16,439,476.59 in the previous period[21] - Cash and cash equivalents at the end of the period increased to ¥259,807,484.08 from ¥225,921,021.74, showing a positive change[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,638,649,780.40, a decrease of 0.83% from ¥1,652,323,039.56 at the end of the previous year[5] - The total assets of Zhejiang Weikang Pharmaceutical Co., Ltd. as of March 31, 2025, amounted to CNY 1,638,649,780.40, a decrease from CNY 1,652,323,039.56 at the beginning of the period[14] - Total current liabilities decreased to CNY 228,091,892.00 from CNY 240,381,545.98, a reduction of about 5.1%[15] - Long-term borrowings increased to CNY 197,372,877.74 from CNY 186,619,205.86, reflecting an increase of approximately 5.7%[15] - The total equity attributable to the parent company decreased to CNY 1,147,811,901.37 from CNY 1,157,666,559.71, a decline of about 0.9%[16] Sales and Expenses - The cash received from sales of goods and services was ¥58,473,216.71, a decrease of 54.16% from ¥127,565,675.80 in the previous year[9] - Total operating revenue decreased to ¥69,775,938.28 from ¥199,953,044.93, representing a decline of approximately 65% year-over-year[17] - Total operating costs decreased to ¥79,431,824.89 from ¥173,888,443.65, a reduction of about 54% year-over-year[17] - The company reported a decrease in sales expenses to ¥30,418,191.53 from ¥52,336,889.43, a reduction of approximately 42% year-over-year[17] - Research and development expenses slightly decreased to ¥2,671,042.00 from ¥2,971,220.93, a decline of about 10% year-over-year[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 11,248, with the largest shareholder holding 60.89% of the shares[10] Asset Impairment and Credit Quality - The company reported a significant increase in asset impairment losses, which rose by 4354.98% to ¥1,541,958.53 compared to -¥34,612.01 in the previous year[9] - The company incurred a credit impairment loss of ¥4,867,447.87 compared to a gain of ¥4,978,010.08 in the previous period, indicating a significant shift in credit quality[18] Government Support and Investments - The company received government subsidies amounting to ¥2,060,338.52 during the reporting period[6] - The total cash inflow from investment activities was ¥44,625,315.68, a decrease from ¥250,969,467.74 in the previous period[21] Market and Product Development - There were no significant updates on new product developments or market expansions mentioned in the conference call[12] - The company did not report any mergers or acquisitions during this period[12]

Group 1: Company Performance - Western Gold achieved operating revenue of 7.001 billion yuan in 2024, a year-on-year increase of 56.68%, and net profit of 290 million yuan, turning from loss to profit [1] - Jihong Co. reported operating revenue of 5.529 billion yuan in 2024, a year-on-year decrease of 17.41%, with net profit down 47.28% to 182 million yuan [2] - Sanli Co. achieved operating revenue of 227 million yuan in 2024, a year-on-year increase of 14.35%, but reported a net loss of 49.88 million yuan, narrowing the loss by 56.50% [2] - Sanli Co. reported operating revenue of 2.590 billion yuan in 2024, a year-on-year increase of 25.25%, with net profit of 68.09 million yuan, up 59.07% [4] - Huaiqi Mountain achieved operating revenue of 1.631 billion yuan in 2024, a year-on-year increase of 15.60%, with net profit of 196 million yuan, up 17.74% [6] - Huayuan Holdings reported operating revenue of 2.449 billion yuan in 2024, a year-on-year increase of 1.60%, with net profit of 70.74 million yuan, up 739% [8] - Hangfa Power achieved operating revenue of 47.880 billion yuan in 2024, a year-on-year increase of 9.48%, but net profit decreased by 39.48% to 860 million yuan [10] - Zhongcai Energy reported operating revenue of 2.324 billion yuan in 2024, a year-on-year decrease of 24.21%, with net profit down 94.70% to 760,240 yuan [10] - Longxing Technology achieved operating revenue of 4.355 billion yuan in 2024, a year-on-year increase of 1.95%, with net profit of 142 million yuan, up 28.70% [11] - Jinying Co. reported operating revenue of 1.308 billion yuan in 2024, a year-on-year decrease of 4.52%, with net profit down 36.73% to 22.35 million yuan [12] - Zhujiang Co. achieved operating revenue of 1.558 billion yuan in 2024, a year-on-year decrease of 52.38%, but net profit turned to profit at 15.57 million yuan [12] - Chuanwang Media reported operating revenue of 288 million yuan in 2024, a year-on-year increase of 20.05%, but net profit decreased by 24.02% to 23.80 million yuan [13] - Ronglian Technology achieved operating revenue of 2.022 billion yuan in 2024, a year-on-year decrease of 14.91%, with net profit of 28.11 million yuan, up 107.87% [13] - Oufeiguang reported operating revenue of 20.437 billion yuan in 2024, a year-on-year increase of 21.19%, but net profit decreased by 24.09% to 58.38 million yuan [14] Group 2: Dividend Proposals - Western Gold proposed a cash dividend of 0.5 yuan per 10 shares [1] - Jihong Co. proposed a cash dividend of 1.58 yuan per 10 shares [2] - Sanli Co. proposed a cash dividend of 1.50 yuan per 10 shares [4] - Huaiqi Mountain proposed a cash dividend of 4.00 yuan per 10 shares [6] - Huayuan Holdings proposed a cash dividend of 1.00 yuan per 10 shares [8] - Hangfa Power proposed a cash dividend of 0.97 yuan per 10 shares [10] - Zhongcai Energy proposed a cash dividend of 0.05 yuan per 10 shares [10] - Longxing Technology proposed a cash dividend of 1.20 yuan per 10 shares [11] - Jinying Co. proposed a cash dividend of 1.00 yuan per 10 shares [12] - Zhujiang Co. proposed a cash dividend of 1.25 yuan per 10 shares [12] - Chuanwang Media proposed a cash dividend of 1.25 yuan per 10 shares [13] - Ronglian Technology proposed a cash dividend of 0.0425 yuan per share [13] - Oufeiguang proposed a cash dividend of 0.0178 yuan per share [14]

Group 1 - The article highlights a list of companies facing various financial difficulties, including those under investigation, continuous losses, and potential delisting risks [2][5] - Approximately 200 companies are mentioned in the "latest risk warning stock list," indicating a significant concern regarding the stability of the A-share market [5][6] - The A-share market experienced a notable decline, with the CSI 2000 index dropping by 1.90%, reflecting investor anxiety and market volatility [5][6] Group 2 - In contrast, the U.S. stock market saw a significant rise, with the Dow Jones Industrial Average increasing by 597.97 points, or 1.42%, indicating a positive market reaction to adjustments in tariff policies by President Trump [6] - The Nasdaq index rose by 404.54 points, or 2.27%, while the S&P 500 index gained 100.01 points, or 1.76%, showcasing a robust performance in the U.S. market [6] - The Nasdaq Golden Dragon China Index showed a slight decline of 0.02%, reflecting the complex dynamics of U.S.-China trade relations and the contrasting sentiments in the two markets [6]

Investment Rating - The industry rating is maintained at "Overweight" [4] Core Viewpoints - The government work report emphasizes new goals for the pharmaceutical industry, focusing on enhancing basic medical services and promoting the development of traditional Chinese medicine (TCM) [3] - The TCM sector experienced a slight decline of 0.76% last week, with the overall pharmaceutical sector showing a broader pullback [1][4] - The TCM sector's current PE (ttm) is 25.84X, with a PB (lf) of 2.24X, indicating a valuation premium of 105.83% relative to the CSI 300 index [2][4] Market Performance - Last week, the TCM sector reported a slight decline, with the TCM II index closing at 6207.73 points, down 0.76% [1] - The overall pharmaceutical sector saw a decline of 2.72%, with the medical services sector experiencing the largest drop at 7.94% [1] Valuation - The TCM sector's PE (ttm) decreased by 0.23X week-on-week, while the PB (lf) decreased by 0.01X [2] - The TCM sector's PE is at the 24.71% percentile and PB at the 4.63% percentile over the past decade [2] Government Policy Impact - The government aims to enhance the quality and accessibility of healthcare services, which is expected to benefit the TCM industry [3] - The report highlights the importance of integrating TCM into the broader healthcare system, promoting a full industry chain from cultivation to consumption [3] Investment Opportunities - The report suggests that the TCM industry may see opportunities arising from price governance and consumption recovery in 2025 [4] - Key investment themes include price governance, consumption recovery, and state-owned enterprise reform, with a focus on companies with strong R&D capabilities and market share [4][8]

文/梧桐小新 2月14日晚，浙江证监局发布《关于对天健会计师事务所（特殊普通合伙） 及相关人员采取出具警示函措施的决定》。 浙江证监局 牵头对天健所开展合规性检 查，并对部分审计项目进行执业质量检查。 经查， 天健 在内部治理、质量控制体系、独立性管理、项目执业质量方面均存在问题： 1、内部治理方面： 一是合伙人委派、轮换等部分内部制度建设及执行不到位；二是在人事、财务和信息管理等方面未充分实施一体化管理。 2、 质量控制体系方面： 一是风险评估程序执行不到位； 二是部分项目与前任注册会计师沟通程序存在缺陷； 三是部分项目审计业务约定书签署不规范； 四是高风险项目连续承接管理不规范； 五是质控人员的客观性和独立性可能存在不利影响； 六是部分项目质量控制复核不到位； 七是业务咨询底稿记录不 完善； 八是部分审计档案归档存在缺陷； 九是部分项目审计底稿超期归档。 3、 独立性管理方面： 一是个别签字注册会计师未按相关规定进行轮换； 二是个别员工未签署独立性声明； 三是内幕信息知情人管理不规范； 四是个别合 伙人及其主要近亲属、员工违规买卖上市公司股票； 五是同一品牌公司管理不规范，存在利益冲突可能。 4、 项目执 ...

目 录 天健审〔2024〕9852 号 浙江维康大药房有限公司全体股东： 一、审计意见 我们审计了浙江维康大药房有限公司（以下简称维康大药房公司）个别财务 报表，包括 2024 年 4 月 30 日的资产负债表，2024 年 1-4 月的利润表、现金流 量表、所有者权益变动表，以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则中与编制个别 财务报表相关的规定编制，公允反映了维康大药房公司 2024 年 4 月 30 日的财务 状况，以及 2024 年 1-4 月的经营成果和现金流量。 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注 册会计师对财务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。 按照中国注册会计师职业道德守则，我们独立于维康大药房公司，并履行了职业 道德方面的其他责任。我们相信，我们获取的审计证据是充分、适当的，为发表 审计意见提供了基础。 | 第 1—3 页 | | --- | | 一、审计报告……………………………………………………… | | 二、财务报表……………………………………………………… 第 | 4— ...

2、注册分类：中药 2.3 类 3、剂型：滴丸剂 证券代码：300878 证券简称：维康药业 公告编号：2024-060 浙江维康药业股份有限公司 关于收到银黄滴丸Ⅱb 期临床试验总结报告的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江维康药业股份有限公司（以下简称"公司"）于近日收到银黄滴丸治疗 复发性口腔溃疡（上焦实热证）的有效性和安全性的多中心、随机、双盲、安慰 剂平行对照Ⅱb 期临床试验的总结报告。现将主要情况公告如下： 一、基本信息 1、药品名称：银黄滴丸 4、适应症：复发性口腔溃疡（上焦实热证） 5、临床试验分期：Ⅱb 期临床试验 6、试验负责单位：湖南中医药大学第一附属医院 7、申办方：浙江维康药业股份有限公司 二、主要研究结论 基于银黄滴丸Ⅱb 期临床研究结果： 用药第 5 天末，靶溃疡愈合率、口腔溃疡愈合率、靶溃疡愈合时间、自觉疼 痛 VAS 评分、靶溃疡激惹痛 VAS 评分、中医证候疗效方面，试验组疗效均显著 优于安慰剂组，组间比较差异均有统计学意义（P＜0.05）。 用药第 5 天末，试验组与安慰剂组在靶溃疡面积较基线变 ...

证券代码：300878 证券简称：维康药业 公告编号：2024-057 三、其他说明 公司控股股东、实际控制人刘忠良先生资信状况良好，具备相应的资金偿还能 力。本次股份解除质押事项不会导致公司实际控制权发生变更，不会对公司生产经 营、公司治理等产生实质性影响。截至本公告披露日，刘忠良先生所质押的股份不 浙江维康药业股份有限公司 关于控股股东、实际控制人部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江维康药业股份有限公司（以下简称"公司"）近日接到公司控股股东、实 际控制人刘忠良先生的通知，获悉其所持有本公司的部分股份办理了解除质押业 务，具体情况如下： | 股东名称 | 是否为控股 股东或第一 | 本次解除 质押股份 | 占其所 | 占公司 | | 解除 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | | 大股东及其 | 数量 | 持股份 | 总股本 | 起始日 | 日期 | | | | 一致行动人 | （股） | 比例 | 比例 | | | | | 刘忠良 | ...

深 圳 证 券 交 易 所 1.你公司2021年至 2023年分别实现净利润 0.97 亿元、 0.45 亿元、-0.06 亿元，同比下降 28.95%、53.94%、116.47%， 净利润自上市次年起连续下滑。你公司 2023 年第四季度实 现净利润-0.77 亿元，为 2023 年亏损的主要原因。你公司未 按本所《创业板股票上市规则》的要求披露 2023 年度业绩 预告。请你公司： （1）详细分析净利润自上市次年起连续下滑的原因， 与同行业可比公司变动趋势是否一致。 （2）详细分析 2023 年第四季度大幅亏损的原因，是否 存在利润调节等情况。 1 关于对浙江维康药业股份有限公司的 年报问询函 创业板年报问询函〔2024〕第 192 号 浙江维康药业股份有限公司董事会 ： 我部在对你公司 2023 年度报告事后审查中关注到以下 情况： （3）补充说明未按规定披露 2023 年度业绩预告的原因， 并自查你公司信息披露工作是否真实、准确、完整、及时等。 请年审会计师对问题（1）（2）进行核查并发表明确意 见。 2.你公司 2023 年财务报告被年审会计师出具了保留意 见的审计报告。由于你公司未能提供完整资料 ...

浙江维康药业股份有限公司 2023 年度内部控制自我评价报告 浙江维康药业股份有限公司 2023 年度内部控制自我评价报告 浙江维康药业股份有限公司全体股东： 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建 立和实施内部控制进行监督，经理层负责组织领导企业内部控制的日常运行。公 司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假 记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个 别及连带法律责任。 公司内部控制的目标是：保证经营管理合法合规、资产安全、财务报告及相 关信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存在 的固有局限性，故仅能为实现上述目标提供合理保证。此外，由于情况的变化可 能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低，根据内部控 制评价结果推测未来内部控制的有效性具有一定的风险。 二、公司内部控制评价结论 根据公司财务报告内部控制缺陷的认定标准，于内部控制评价报告基准日， 报告期内公司发现财务报告内部控制重要缺陷 1 ...